The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents

Oncologist

Volumn 18, Issue 2, 2013, Pages 115-122

  Robinson, Kyle W ^a   Sandler, Alan B ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Epidermal growth factor receptor tyrosine kinase inhibitor; Hepatocyte growth factor; MET; Non small cell lung cancer; Tyrosine kinase inhibitor

Indexed keywords

5 (2, 6 DICHLOROBENZYLSULFONYL) 3 [3, 5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1, 3 DIHYDRO 2H INDOL 2 ONE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANTINEOPLASTIC AGENT; CABOZANTINIB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; FICLATUZUMAB; GEFITINIB; H 224G11; MGCD 265; N (3 CHLOROPHENYL) 3 [3, 5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2, 3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; NAVELBINE; ONARTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; SGX 523; TIVANTINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

APOPTOSIS; CELL PROLIFERATION; DRUG RESPONSE; DRUG SAFETY; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

EID: 84874345305     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0262     Document Type: Review

References (57)

1. Surveillance, Epidemiology, and End Results. Table 1.1. Estimated New Cancer Cases and Deaths for 2010. All Races, By Sex. Available at http://seer.cancer.gov/csr/1975_2007/results_single/sect_01_table.01.pdf, accessed September 4, 2012.
2. Ma PC, Jagadeeswaran R, Jagadeesh S et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005;65:1479-1488.
3. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small- cell lung cancer. N Engl J Med 2006;355:2542-2550.
4. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small- cell lung cancer. J Clin Oncol 2008;26:3543-3551.
5. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
7. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
8. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362: 2380-2388.
9. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non- small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
10. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small- cell lung cancer (OPTIMAL, CTONG-0802): A multi- centre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-742.
11. Bean J, Brennan C, Shih JY et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007;104:20932-20937.
12. Hammerman PS, Jänne PA, Johnson BE. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2009;15:7502-7509.
13. Jackman DM, Miller VA, Cioffredi LA et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumor registry of clinical trials. Clin Cancer Res 2009;15:5267-5273.
14. Raponi M, Winkler H, Dracopoli NC. KRAS mutations predict response to EGFR inhibitors. Curr Opin Pharmacol 2008;8:413-418.
15. Balak MN, Gong Y, Riely GJ et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12:6494-6501.
16. Bean J, Riely GJ, Balak M et al. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 2008;14:7519-7525.
17. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043.
18. Wang W, Li Q, Takeuchi S et al. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res 2012;18:1663-1671.
19. Yamada T, Matsumoto K, Wang W et al. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin Cancer Res 2010;16:174-183.
20. Yamada T, Takeuchi S, Kita K et al. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. J Thorac Oncol 2012;7:272-280.
21. Yano S, Wang W, Li Q et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008;68:9479-9487.
22. Yano S, Yamada T, Takeuchi S et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 2011;6:2011-2017.
23. Kris MG, Johnson BE, Kwiatkowski DJ et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2011;29(suppl 18):CRA7506.
24. Cipriani NA, Abidoye OO, Vokes E et al. MET as a target for treatment of chest tumors. Lung Cancer 2009;63:169-179.
25. Ma PC, Maulik G, Christensen J et al. c-Met: Structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003;22:309-325.
26. Boccaccio C, Comoglio PM. Invasive growth: A MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006;6:637-645.
27. Furge KA, Kiewlich D, Le P et al. Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc Natl Acad Sci U S A 2001;98:10722-10727.
28. Moghul A, Lin L, Beedle A et al. Modulation of c-MET proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: Evidence for rapid decay of the 8 kb c-MET transcript. Oncogene 1994;9:2045-2052.
29. Pennacchietti S, Michieli P, Galluzzo M et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347-361.
30. Okuda K, Sasaki H, Yukiue H et al. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci 2008;99:2280-2285.
31. Cappuzzo F, Marchetti A, Skokan M et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009;27:1667-1674.
32. Lutterbach B, Zeng Q, Davis LJ et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 2007;67:2081-2088.
33. Munshi N, Jeay S, Li Y et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010;9:1544-1553.
34. Goetsch L, Lepecquet A-M, Geronimi F et al. First bivalent fully antagonist anti-c-Met antibody targeting the c-Met receptor: II) in vivo activity. Proc Am Assoc Cancer Res 2009;2009:2792.
35. Puri N, Khramtsov A, Ahmed S et al. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res 2007;67:3529-3534.
36. Yang Y, Wislez M, Fujimoto N et al. A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther 2008;7:952-960.
37. Arcila ME, Oxnard GR, Nafa K et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011;17:1169-1180.
38. Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
39. Mark M, Zhang Y-W, Su Y et al. Combination efficacy with MetMAb and erlotinib in a NSCLC tumor model highlight therapeutic opportunities for c-Met inhibitors in combination with EGFR inhibitors. Presented at the 99th American Association for Cancer Research Annual Meeting, San Diego, CA, April 12-16, 2008.
40. Arteaga CL. HER3 and mutant EGFR meet MET. Nat Med 2007;13:675-677.
41. Benedettini E, Sholl LM, Peyton M et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol 2010; 177:415-423.
42. Kyowa Hakko Kirin Co. Ltd.,Tokyo, Japan. Data on file.
43. Stabile LP, Rothstein ME, Keohavong P et al. Targeting of both the c-Met and EGFR pathways results in additive inhibition of lung tumorigenesis in transgenic mice. Cancers (Basel) 2010;2:2153-2170.
44. Zhang YW, Staal B, Essenburg C et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res 2010;70: 6880-6890.
45. Fournel M, Dupont I, Bonfils C et al. Potent preclinical anti-tumor activity of MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor in phase II clinical development, in combination with an EGFR inhibitor. Proc Am Assoc Cancer Res 2010; 70(suppl 1):3612.
46. Janne PA, Wax M, Leach JW et al. Targeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: Impact of preclinical studies on clinical trial design. Eur J Cancer Suppl 2008;6:174.
47. Tang Z, Du R, Jiang S et al. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 2008;99:911-922.
48. Wakelee HA, Gettinger SN, Engelman JA et al. A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28(suppl 15):3017.
49. Tan E, Park K, Lim WT et al. Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. J Clin Oncol 2011;29(suppl 15):7571.
50. Goldman J, Laux I, Chai F et al. Phase 1 dose- escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer 2012;118:5901-5911.
51. Spigel DR, Ervin TJ, Ramlau R et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 2011;29(suppl 15):7505.
52. Sequist LV, von Pawel J, Garmey EG et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011;29: 3307-3315.
53. Yasenchak C, Nackaerts K, Awada A et al. Phase 2 results of XL184 in a cohort of patients (pts) with advanced non-small cell lung cancer (NSCLC). Eur J Cancer Suppl 2010;8:126.
54. Mok T, Tan E, Park K et al. Randomized phase II study of ficlatuzumab (formerly AV-299), an antihepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. J Clin Oncol 2011; 29(suppl 15):TPS213.
55. Yu W, Pandita A, Penuel E et al. Exploratory biomarker analyses from OAM4558g: A placebo- controlled phase II study of erlotinib with or without MetMAb in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29(## suppl): 7529.
56. Sandler A, Schiller JH, Hirsh V et al. A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29(suppl 15):TPS217.
57. Rodig S, Sequist LV, von Pawel J et al. An exploratory biomarker analysis evaluating the effect of the c-MET inhibitor tivantinib (ARQ 197) and erlotinib in NSCLC patients in a randomized, double-blinded phase 2 study. Presented at the Annual Meeting of the American Association for Cancer Research, Chicago, IL, March 31-April 4, 2012.